BACKGROUND AND AIMS: Surgery followed by platinum-taxane chemotherapy is the current standard approach to treat advanced ovarian cancer. The impact of the time interval between surgery and initiation of chemotherapy for clinical outcome has not been clarified yet. METHODS: Individual patient data analysis of 3326 patients from three prospective randomised phase III trials conducted between 1995 and 2002 to investigateplatinum-taxane based chemotherapy regimens in advanced ovarian cancer. Time to chemotherapy (TTC) was analysed and correlated with outcome. RESULTS: Median TTC was 19 days (range 1-56). The effect of TTC differed significantly for patients with or without residual disease for progression-free (PFS; interaction p=0.004) and for overall survival (OS; interaction p=0.028). A delayed start of chemotherapy was associated with earlier disease recurrence (HR 1.038, 95% CI 0.973; 1.106, p=0.257 per week delay) and a significantly decreased OS (HR 1.087, 95% CI 1.005; 1.176 p=0.038) in patients with no residual tumour after surgery. In contrast, in patients with residual disease, a longer TTC was significantly associated with later progression (HR 0.931, 95% CI 0.895; 0.969, p<0.001) and no effect towards OS (HR 0.983, 95% CI 0.940; 1.028, p=0.452). CONCLUSIONS: Our results provide evidence that early initiation of chemotherapy might result in slightly improved survival in patients with complete cytoreduction while patients with residual disease after surgery did not benefit from earlier chemotherapy. A prospective study randomising patients to different time intervals could clarify the definitive relevance of the time between surgery and chemotherapy.
RCT Entities:
BACKGROUND AND AIMS: Surgery followed by platinum-taxane chemotherapy is the current standard approach to treat advanced ovarian cancer. The impact of the time interval between surgery and initiation of chemotherapy for clinical outcome has not been clarified yet. METHODS: Individual patient data analysis of 3326 patients from three prospective randomised phase III trials conducted between 1995 and 2002 to investigate platinum-taxane based chemotherapy regimens in advanced ovarian cancer. Time to chemotherapy (TTC) was analysed and correlated with outcome. RESULTS: Median TTC was 19 days (range 1-56). The effect of TTC differed significantly for patients with or without residual disease for progression-free (PFS; interaction p=0.004) and for overall survival (OS; interaction p=0.028). A delayed start of chemotherapy was associated with earlier disease recurrence (HR 1.038, 95% CI 0.973; 1.106, p=0.257 per week delay) and a significantly decreased OS (HR 1.087, 95% CI 1.005; 1.176 p=0.038) in patients with no residual tumour after surgery. In contrast, in patients with residual disease, a longer TTC was significantly associated with later progression (HR 0.931, 95% CI 0.895; 0.969, p<0.001) and no effect towards OS (HR 0.983, 95% CI 0.940; 1.028, p=0.452). CONCLUSIONS: Our results provide evidence that early initiation of chemotherapy might result in slightly improved survival in patients with complete cytoreduction while patients with residual disease after surgery did not benefit from earlier chemotherapy. A prospective study randomising patients to different time intervals could clarify the definitive relevance of the time between surgery and chemotherapy.
Authors: L Rodríguez-Ortiz; A Arjona-Sánchez; M Ibañez-Rubio; J Sánchez-Hidalgo; A Casado-Adam; S Rufián-Peña; J Briceño-Delgado Journal: Surg Endosc Date: 2020-04-23 Impact factor: 4.584
Authors: John K Chan; James J Java; Katherine Fuh; Bradley J Monk; Daniel S Kapp; Thomas Herzog; Jeffrey Bell; Robert Young Journal: Gynecol Oncol Date: 2016-10-19 Impact factor: 5.482
Authors: Andrew Bryant; Shaun Hiu; Patience T Kunonga; Ketankumar Gajjar; Dawn Craig; Luke Vale; Brett A Winter-Roach; Ahmed Elattar; Raj Naik Journal: Cochrane Database Syst Rev Date: 2022-09-26
Authors: Arlene E Garcia-Soto; James J Java; Wilberto Nieves Neira; J Matthew Pearson; David E Cohn; Shashikant B Lele; Krishnansu S Tewari; Joan L Walker; Angeles Alvarez Secord; Deborah K Armstrong; Larry J Copeland Journal: Gynecol Oncol Date: 2016-10-07 Impact factor: 5.482
Authors: Paul D P Pharoah; Honglin Song; Ed Dicks; Maria P Intermaggio; Patricia Harrington; Caroline Baynes; Kathryn Alsop; Natalia Bogdanova; Mine S Cicek; Julie M Cunningham; Brooke L Fridley; Aleksandra Gentry-Maharaj; Peter Hillemanns; Shashi Lele; Jenny Lester; Valerie McGuire; Kirsten B Moysich; Samantha Poblete; Weiva Sieh; Lara Sucheston-Campbell; Martin Widschwendter; Alice S Whittemore; Thilo Dörk; Usha Menon; Kunle Odunsi; Ellen L Goode; Beth Y Karlan; David D Bowtell; Simon A Gayther; Susan J Ramus Journal: J Natl Cancer Inst Date: 2016-01-27 Impact factor: 13.506
Authors: Shengqing Gu; Stephanie Lheureux; Azin Sayad; Paulina Cybulska; Liat Hogen; Iryna Vyarvelska; Dongsheng Tu; Wendy R Parulekar; Matthew Nankivell; Sean Kehoe; Dennis S Chi; Douglas A Levine; Marcus Q Bernardini; Barry Rosen; Amit Oza; Myles Brown; Benjamin G Neel Journal: Proc Natl Acad Sci U S A Date: 2021-06-22 Impact factor: 11.205